---
title: "Major Investor Makes Bold New Move into TRex Bio Stock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301782322.md"
description: "SVLSF VI, LLC increased its stake in TRex Bio (TRXB) by purchasing 92,857 shares worth approximately $1.3 million on October 13, 2026. This insider activity signals growing investor confidence following the company's recent IPO priced at $14. Despite cautious market conditions, TRex Bio shares traded modestly above the IPO price, supported by new governance structures and a current market cap of $385.1M."
datetime: "2026-10-14T02:03:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301782322.md)
  - [en](https://longbridge.com/en/news/301782322.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301782322.md)
generator: "portal-rs"
---

# Major Investor Makes Bold New Move into TRex Bio Stock

New insider activity at TRex Bio, Inc. ( (TRXB) ) has taken place on October 13, 2026.

Significant shareholder SVLSF VI, LLC has increased its stake in TRex Bio, Inc., purchasing 92,857 shares of the company’s stock in a recent transaction. The deal, valued at $1,299,998, underscores a notable capital commitment and may signal growing confidence in TRex Bio’s future prospects from one of its key investors.

TRex Bio’s shares have seen modest first-day trading, hovering just above their $14 IPO price, after opening indications between about $13.90 and $14.50 as investors gauged demand for the new biotech listing. The IPO was priced at the low end of its range amid cautious market conditions, while the company simultaneously implemented a new charter and bylaws to support a flexible capital structure and more standardized public‑company governance, which may factor into analysts’ evolving valuation frameworks.

**More about TRex Bio, Inc.**

**YTD Price Performance:** 0.21%

**Average Trading Volume:** 723,771

**Current Market Cap:** $385.1M

### Related Stocks

- [TRXB.US](https://longbridge.com/en/quote/TRXB.US.md)

## Related News & Research

- [TRXB’s TRB-061 Drives Analyst Confidence as the $20 Price Target Remains Unchanged](https://longbridge.com/en/news/305821317.md)
- [Eli Lilly Discloses Investment at TRex Bio with 19.9% Stake](https://longbridge.com/en/news/302143708.md)
- [TRex Bio Updates Governance Structure Following IPO Transition](https://longbridge.com/en/news/301757837.md)
- [BUZZ-Street View: Nvidia's AI story intact despite uncertainty at top](https://longbridge.com/en/news/305945171.md)
- [Ferrari Group Announces Acquisition of Remaining 50% Stake in Americas](https://longbridge.com/en/news/306002876.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**